DiaMedica Inc., has announced that John M. Amatruda, M.D. has joined the company's Scientific Advisory Board ("SAB"), enhancing DiaMedica's experienced advisory team.
Dr. Amatruda was the former Senior Vice President and Franchise Head for Diabetes and Obesity at Merck Research Laboratories where he lead the development and regulatory approvals of Januvia™ and Janumet™ - the first compounds in the DPP-IV inhibitor class for Type 2 diabetes.
Prior to Dr. Amatruda's tenure at Merck, he served as Vice President and Therapeutic Area Research Head for the Metabolic Disorders Research at Bayer AG, as well as a Professor of Medicine at the University of Rochester School of Medicine and an Adjunct Professor of Medicine at Yale University School of Medicine.
He is board certified in internal medicine, endocrinology and metabolism. Dr. Amatruda is an author on over 150 scientific papers, abstracts, reviews and book chapters.
"We are extremely pleased to be adding a world leader in diabetes drug development to our SAB," stated Mr. Rick Pauls, President and CEO, DiaMedica Inc.
Mr. Pauls continued, "Dr. Amatruda's opinion is highly respected within the pharmaceutical industry."
"It is a pleasure to join the SAB of DiaMedica," commented Dr. Amatruda. "DiaMedica has several approaches for the treatment of diabetes and I am excited to work with the company and its scientific advisors."